Is Ketorolac Hepatotoxic?
Ketorolac carries minimal hepatotoxic risk in clinical practice, with clinically significant liver injury being rare in the general population. 1
Hepatotoxicity Profile
The hepatotoxic potential of ketorolac is substantially lower compared to other NSAIDs:
Clinically significant hepatotoxicity from NSAIDs, including ketorolac, is rare in the general population. 1
Borderline elevations of liver enzymes may occur in up to 15% of patients taking NSAIDs including ketorolac, but these are typically transient or remain unchanged with continued therapy. 2
Notable elevations of ALT or AST (approximately three times the upper limit of normal) occur in only about 1% of patients in clinical trials with NSAIDs. 2
Evidence from Large-Scale Studies
The most robust evidence comes from a large postmarketing study:
A study of 10,272 courses of parenteral ketorolac found no evidence of hepatotoxic effects in the hospital setting. The incidence of liver injury was actually lower in the ketorolac group (1.0%) compared to the opioid comparison group (1.2%), with an adjusted rate ratio of 0.77. 3
No duration-response or dose-response relationship was identified for hepatotoxicity. 3
No susceptible subgroups were identified who were at increased risk of hepatotoxic effects from parenteral ketorolac. 3
Serious but Rare Hepatic Reactions
While uncommon, severe reactions have been documented:
Rare cases of severe hepatic reactions have been reported, including jaundice, fatal fulminant hepatitis, liver necrosis, and hepatic failure, some with fatal outcomes. 2
These severe reactions are idiosyncratic and unpredictable, not dose-dependent. 2
Comparison to Other NSAIDs
Ketorolac's hepatotoxic profile differs from certain other NSAIDs:
Some NSAIDs, particularly sulindac and diclofenac, show higher rates of hepatic injury and transaminase elevation compared to ketorolac. 1
Ketorolac has been linked to greater GI toxicity due to its prolonged half-life and enterohepatic circulation, but this does not translate to increased hepatotoxicity. 4
Clinical Monitoring Recommendations
Ketorolac should be used with caution in patients with impaired hepatic function or a history of liver disease. 2
Key monitoring parameters include:
Patients with symptoms suggesting liver dysfunction (nausea, fatigue, lethargy, pruritus, jaundice, right upper quadrant tenderness, flu-like symptoms) should have ketorolac discontinued immediately. 2
If abnormal liver tests persist or worsen, or if systemic manifestations occur (eosinophilia, rash), ketorolac should be discontinued. 2
Routine liver function monitoring is not required in patients without risk factors or symptoms. 2
Common Pitfall to Avoid
Do not confuse ketorolac's well-documented GI toxicity with hepatotoxicity—the drug is associated with significant gastrointestinal bleeding risk, particularly in elderly patients and at higher doses, but this does not indicate liver injury. 4, 2